Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Statins lead the way

The Heart of Inflammation

Statins lead the way

The involvement of inflammation in the etiology of coronary artery disease has led to the development of anti-inflammatory compounds to prevent or treat atherosclerosis and acute coronary syndrome. As yet, there is no conclusive evidence from a large, controlled trial showing the clinical benefit of a cardiovascular compound specifically designed as an anti-inflammatory. However, results from recent statin trials indicate that their anti-inflammatory activity plays a significant role in improving clinical outcomes, thus lending support to the hypothesis.

Statins inhibit the activity of HMG-CoA reductase - a rate-limiting enzyme in the synthesis of cholesterol - resulting in decreased intracellular cholesterol. In turn, this leads to the upregulation of LDL receptor activity, which ultimately

Read the full 1191 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers